A randomised, open, placebo controlled 5 way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR).
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2018
At a glance
- Drugs GSK 256066 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 08 Nov 2007 Status changed from recruiting to completed.